JPWO2021153747A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021153747A5 JPWO2021153747A5 JP2021574696A JP2021574696A JPWO2021153747A5 JP WO2021153747 A5 JPWO2021153747 A5 JP WO2021153747A5 JP 2021574696 A JP2021574696 A JP 2021574696A JP 2021574696 A JP2021574696 A JP 2021574696A JP WO2021153747 A5 JPWO2021153747 A5 JP WO2021153747A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- nucleosides
- pharmacologically acceptable
- acceptable salt
- modified oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025165295A JP2026004436A (ja) | 2020-01-31 | 2025-10-01 | Ａｔｎ１のアンチセンスオリゴヌクレオチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020015521 | 2020-01-31 | ||
| JP2020015521 | 2020-01-31 | ||
| JP2020183718 | 2020-11-02 | ||
| JP2020183718 | 2020-11-02 | ||
| PCT/JP2021/003293 WO2021153747A1 (ja) | 2020-01-31 | 2021-01-29 | Ａｔｎ１のアンチセンスオリゴヌクレオチド |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025165295A Division JP2026004436A (ja) | 2020-01-31 | 2025-10-01 | Ａｔｎ１のアンチセンスオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021153747A1 JPWO2021153747A1 (https=) | 2021-08-05 |
| JPWO2021153747A5 true JPWO2021153747A5 (https=) | 2023-11-21 |
| JP7753106B2 JP7753106B2 (ja) | 2025-10-14 |
Family
ID=77079145
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574696A Active JP7753106B2 (ja) | 2020-01-31 | 2021-01-29 | Ａｔｎ１のアンチセンスオリゴヌクレオチド |
| JP2025165295A Pending JP2026004436A (ja) | 2020-01-31 | 2025-10-01 | Ａｔｎ１のアンチセンスオリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025165295A Pending JP2026004436A (ja) | 2020-01-31 | 2025-10-01 | Ａｔｎ１のアンチセンスオリゴヌクレオチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230127437A1 (https=) |
| EP (1) | EP4098747A4 (https=) |
| JP (2) | JP7753106B2 (https=) |
| KR (1) | KR20220133925A (https=) |
| CN (1) | CN114929876A (https=) |
| AU (1) | AU2021212949A1 (https=) |
| CA (1) | CA3169474A1 (https=) |
| WO (1) | WO2021153747A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023112931A1 (ja) * | 2021-12-13 | 2023-06-22 | 日本新薬株式会社 | ＡＴＮ１ ｍＲＮＡ又はｐｒｅ－ｍＲＮＡを標的とするアンチセンスオリゴヌクレオチド |
| WO2023164656A2 (en) * | 2022-02-25 | 2023-08-31 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating atn1 expression |
| WO2023201281A2 (en) * | 2022-04-14 | 2023-10-19 | University Of Massachusetts | Oligonucleotides for atn1 modulation |
| WO2025043202A1 (en) * | 2023-08-23 | 2025-02-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atn1 expression |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3781879B2 (ja) | 1996-11-18 | 2006-05-31 | 武 今西 | 新規ヌクレオチド類縁体 |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| WO2008029619A1 (fr) | 2006-09-07 | 2008-03-13 | Daiichi Sankyo Company, Limited | Oligonucléotide antisens ena ayant une action spécifique de la séquence |
| CA2666191C (en) | 2006-10-09 | 2017-07-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
| ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| CA2693742A1 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| EP2601294B1 (en) * | 2010-08-05 | 2018-11-28 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins |
| CN103562215B (zh) * | 2011-04-01 | 2017-04-26 | 埃西斯药品公司 | 信号转导及转录激活蛋白3(stat3)表达的调节 |
| JP6112569B2 (ja) | 2011-12-16 | 2017-04-12 | 国立大学法人 東京医科歯科大学 | キメラ２重鎖核酸 |
| US20150141320A1 (en) * | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| US10435430B2 (en) | 2013-07-31 | 2019-10-08 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| WO2016127002A1 (en) | 2015-02-04 | 2016-08-11 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
| US20210052631A1 (en) | 2015-09-25 | 2021-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| JPWO2017068791A1 (ja) | 2015-10-23 | 2018-08-09 | レナセラピューティクス株式会社 | 少なくとも１つのバルジ構造を有する核酸複合体 |
| JPWO2017068790A1 (ja) | 2015-10-23 | 2018-08-09 | レナセラピューティクス株式会社 | 核酸複合体 |
| AU2016344609B2 (en) * | 2015-10-28 | 2022-05-12 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of duchenne muscular dystrophy |
| WO2017131124A1 (ja) | 2016-01-26 | 2017-08-03 | 日産化学工業株式会社 | 一本鎖オリゴヌクレオチド |
| EP3418289B1 (en) | 2016-02-17 | 2026-04-08 | Institute Of Science Tokyo | Artificial nucleoside and artificial nucleotide, and artificial oligonucleotide |
| JPWO2018003739A1 (ja) | 2016-06-30 | 2019-04-18 | レナセラピューティクス株式会社 | 機能的リガンドを含む核酸複合体 |
| AU2018215440B2 (en) | 2017-02-06 | 2024-10-24 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| EP3587576A4 (en) | 2017-02-21 | 2021-01-06 | Osaka University | ANTISENSE OLIGONUCLEIC ACID |
| EP3585900B1 (en) * | 2017-02-22 | 2022-12-21 | CRISPR Therapeutics AG | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
| BR112020001430A2 (pt) | 2017-07-26 | 2020-07-28 | Nissan Chemical Corporation | oligonucleotídeo de fita simples |
| BR112020018902A2 (pt) * | 2018-03-20 | 2021-01-26 | Tokyo Institute Of Technology | oligonucleotídeo antissenso com toxicidade reduzida |
-
2021
- 2021-01-29 KR KR1020227029055A patent/KR20220133925A/ko active Pending
- 2021-01-29 CN CN202180008680.XA patent/CN114929876A/zh active Pending
- 2021-01-29 US US17/795,867 patent/US20230127437A1/en active Pending
- 2021-01-29 JP JP2021574696A patent/JP7753106B2/ja active Active
- 2021-01-29 EP EP21747552.4A patent/EP4098747A4/en active Pending
- 2021-01-29 CA CA3169474A patent/CA3169474A1/en active Pending
- 2021-01-29 AU AU2021212949A patent/AU2021212949A1/en active Pending
- 2021-01-29 WO PCT/JP2021/003293 patent/WO2021153747A1/ja not_active Ceased
-
2025
- 2025-10-01 JP JP2025165295A patent/JP2026004436A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021153747A5 (https=) | ||
| JP6884250B2 (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| US11542501B2 (en) | Antisense oligonucleotides targeting ATXN3 | |
| JPWO2020209285A5 (https=) | ||
| JP6954843B2 (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| JP6542662B2 (ja) | オリゴヌクレオチドアナログのボロン酸結合体 | |
| US5849900A (en) | Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids | |
| WO2021207641A1 (en) | Antisense oligonucleotide (aso) molecules and uses thereof for coronavirus diseases | |
| TW200817514A (en) | ENA antisense oligonucleotides exhibiting sequence-specification | |
| CA3141874A1 (en) | Modified gapmer oligonucleotides and methods of use | |
| JP7753106B2 (ja) | Ａｔｎ１のアンチセンスオリゴヌクレオチド | |
| JP2021072862A5 (https=) | ||
| JP2021505129A5 (https=) | ||
| AR127325A1 (es) | Métodos y composiciones para el tratamiento de la enfermedad renal poliquística | |
| TW202020152A (zh) | 調節rtel1表現之寡核苷酸 | |
| US20230054720A1 (en) | Antisense Oligonucleotides Targeting ATXN3 | |
| JP2024522147A5 (https=) | ||
| US20240336920A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| WO2021177418A1 (ja) | Ｃａｌｍ２のアンチセンスオリゴヌクレオチド | |
| WO2020038973A1 (en) | Antisense oligonucleotides targeting sptlc1 | |
| CN119032175A (zh) | 经修饰的间隔体寡聚物及其使用的方法 | |
| US20230060373A1 (en) | Antisense Oligonucleotides Targeting ATXN3 | |
| EP4426833A1 (en) | Oligonucleotides for modulating apolipoprotein e4 expression | |
| EP4332221A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| WO2024257848A1 (ja) | 遅発性中枢毒性が低減されているアンチセンスオリゴヌクレオチドの設計方法、及びその製造方法 |